245 results
424B5
TPST
Tempest Therapeutics Inc
20 Jun 24
Prospectus supplement for primary offering
8:32am
will describe in the prospectus supplement, naming the underwriter, the nature of any such relationship.
We may sell securities directly or through agents we
8-K
EX-99.1
TPST
Tempest Therapeutics Inc
20 Jun 24
Tempest Unveils New Survival Data for Amezalpat (TPST-1120) in Randomized First-Line HCC Study Demonstrating a Six-Month Improvement over Control Arm
8:13am
. Nature Reviews Disease Primers. 2021, 7(1), 6.
Nine out of ten cases of HCC are caused by chronic liver disease, which includes chronic hepatitis B and C … Therapeutics. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events
8-K
EX-99.1
TPST
Tempest Therapeutics Inc
9 May 24
Tempest Reports First Quarter 2024 Financial Results and Provides Business Update
4:25pm
that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “may,” “will,” “should,” “would
8-K
EX-99.1
bpkzow07jxx9
19 Mar 24
Tempest Reports Year End 2023 Financial Results and Provides Business Update
4:10pm
8-K
EX-99.1
e4hbp9kx
8 Nov 23
Tempest Reports Third Quarter 2023 Financial Results and Provides Business Update
5:18pm
8-K
EX-99.2
i1yf2q asqp
11 Oct 23
Entry into a Material Definitive Agreement
8:13am
8-K
EX-99.1
xsb s2mslsfymop1gs
11 Oct 23
Entry into a Material Definitive Agreement
8:13am
8-K
EX-4.1
ur5627y5qzpl fwoys0
11 Oct 23
Entry into a Material Definitive Agreement
8:13am
8-K
EX-99.1
wyrtnv
10 Aug 23
Tempest Reports Second Quarter 2023 Financial Results and Provides Business Update
4:27pm
8-K
EX-99.1
k07jyoyrcibbnq2sts7
10 May 23
Tempest Reports First Quarter 2023 Financial Results and Provides Business Update
4:21pm